Twist Bioscience Launches Express Genes Rapid Gene Synthesis Service
14 Novembro 2023 - 10:00AM
Business Wire
Clonally perfect genes shipped in as few as
five business days
Launch of ‘fast genes’ enabled by
state-of-the-art Wilsonville manufacturing facility
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling
customers to succeed through its offering of high-quality synthetic
DNA using its silicon platform, today announced the launch of Twist
Express Genes, a new leading gene synthesis service with an order
to shipping turnaround time of five to seven business days.1
“Twist Express Genes is our first new offering enabled by the
increased capacity and streamlined processes in our Wilsonville
facility. We are now able to deliver the same NGS-verified clonally
perfect genes that our customers have come to expect from Twist in
about half the time, at an unprecedented scale. We offer the rapid
turnaround that our customers need in multiple formats and at the
same speed for one or thousands of genes. With this new offering,
we will focus initially on our current customers who we know are
making some of their own genes,” said Emily M. Leproust, Ph.D., CEO
and co-founder of Twist Bioscience. “We look forward to enabling
the ‘Maker’s Market’ to continue to push the boundaries of what’s
possible, working to uncover new therapeutic modalities for
devastating diseases, ushering in sustainable applications for
enzyme engineering and chemical development, and much more. They
clone their own genes because otherwise they would have to delay
their research while waiting for genes they ordered, and now they
won’t have to make that compromise.”
Twist leverages its ability to miniaturize the chemical reaction
to creating DNA using its silicon-based DNA synthesis platform
along with expertise, software, honed processes and the expanded
layout of its Wilsonville facility to deliver clonal genes and gene
fragments at scale and with rapid turnaround times. Twist will
utilize dynamic pricing for Express Genes, charging a premium price
for speed, which will be determined by market demand and
manufacturing capacity. Customers will be able to place orders for
Express Genes through Twist’s ecommerce platform.
“We surveyed several hundred gene users and found that in
addition to those who make their own genes entirely, a large
portion of respondents both purchase DNA from a supplier and in
parallel make their own,” said Anne St Louis, Director at Percepta
Associates Inc.2 “These data suggest that there is a market to
capture from researchers in industry and academia who currently use
vendors for only part of their total gene production.”
"As a gene therapy startup developing programmable RNA
medicines, we routinely generate diverse and customized DNA
sequences to advance our technologies and enable application to
multiple disease targets. Being able to order sequence-verified
large synthetic gene constructs in just one week expands what we
can screen and allows faster iterations of the design-build-test
cycle," said Susan Byrne, Senior Principal Scientist, Shape
Therapeutics.
Twist Express Genes
Twist Express Genes are 0.3 to 5.0kb in length. Due to scale
enabled by Twist’s platform, orders of any size both small and
large can be filled, and as with standard speed Twist Clonal Genes,
Twist Express Genes are NGS sequence-verified as one hundred
percent accurate. Twist Express Genes can be cloned into catalog
vectors or custom vectors so that customers can move right to
experimentation. They can also be shipped in customers’ preferred
delivery formats, including tube and plate.
Current turnaround times for some Twist Bioscience
products:
- Express Genes: order to shipping starting at 5 business
days
- Standard speed Clonal Genes: starting at 10 business days
- Gene Fragments: starting at 2 business days with an error rate
of 1:7,5003
- Oligo Pools up to 300nt: starting at 3 business days with an
error rate of 1:3,0004
Twist quantified the minimal carbon footprint of manufacturing a
single gene in its 2023 ESG report. View the report here:
https://www.twistbioscience.com/company/esg?tab=environmental
1Express Genes ship in 5-7
business days. This time will vary based on complexity and length
of the sequence. Orders placed outside of the US may incur
additional delivery turnaround time.
2Research funded by Twist
Bioscience
3Error rate from
https://www.twistbioscience.com/products/genes?tab=fragment
4Error rate from
https://www.twistbioscience.com/products/oligopools?tab=oligo-pools
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic
biology and genomics company that has developed a disruptive DNA
synthesis platform to industrialize the engineering of biology. The
core of the platform is a proprietary technology that pioneers a
new method of manufacturing synthetic DNA by “writing” DNA on a
silicon chip. Twist is leveraging its unique technology to
manufacture a broad range of synthetic DNA-based products,
including synthetic genes, tools for next-generation sequencing
(NGS) preparation, and antibody libraries for drug discovery and
development. Twist is also pursuing longer-term opportunities in
digital data storage in DNA and biologics drug discovery. Twist
makes products for use across many industries including healthcare,
industrial chemicals, agriculture and academic research.
Follow us on Twitter | Facebook | LinkedIn | YouTube
Twist Bioscience Legal Notice Regarding Forward-Looking
Statements
This press release contains forward-looking statements. All
statements other than statements of historical facts contained
herein, including statements regarding the turnaround time of the
Twist Express Gene product, and Twist’s ability to service
researchers currently making their own genes, are forward-looking
statements reflecting the current beliefs and expectations of
management made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. Forward-looking
statements involve known and unknown risks, uncertainties, and
other important factors that may cause Twist Bioscience’s actual
results, performance, or achievements to be materially different
from any future results, performance, or achievements expressed or
implied by the forward-looking statements. Such risks and
uncertainties include, among others, the ability to achieve the
expected benefits of Twist Bioscience’s workforce reduction and
reduced investments in DNA data storage; the ability to attract new
customers and retain and grow sales from existing customers; the
ability of Twist to achieve sufficient revenue to achieve or
maintain positive cash flow from operations or profitability in any
given period; risks and uncertainties of rapidly changing
technologies and extensive competition in synthetic biology that
could make the products Twist Bioscience is developing obsolete or
non-competitive; uncertainties of the retention of significant
customers; the ability of Twist Bioscience to successfully
integrate acquired companies and to achieve expected benefits from
acquisitions; supply chain and other disruptions caused by the
COVID-19 pandemic or otherwise; risks of third party claims
alleging infringement of patents and proprietary rights or seeking
to invalidate Twist Bioscience’s patents or proprietary rights; and
the risk that Twist Bioscience’s proprietary rights may be
insufficient to protect its technologies. For a description of the
risks and uncertainties that could cause actual results to differ
from those expressed in these forward-looking statements, as well
as risks relating to Twist Bioscience’s business in general, see
Twist Bioscience’s risk factors set forth in Twist Bioscience’s
Quarterly Report on Form 10-Q filed with the Securities and
Exchange Commission on August 7, 2023 and subsequent filings with
the SEC. Any forward-looking statements contained in this press
release speak only as of the date hereof, and Twist Bioscience
specifically disclaims any obligation to update any forward-looking
statement, whether as a result of new information, future events or
otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231114228857/en/
For Investors: Angela Bitting SVP, Corporate Affairs
925-202-6211 abitting@twistbioscience.com
For Media: Amanda Houlihan Communications Generalist
774-265-5334 ahoulihan@twistbioscience.com
Twist Bioscience (NASDAQ:TWST)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Twist Bioscience (NASDAQ:TWST)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024